Felbamate in experimental model of status epilepticus

Epilepsia

Volumn 41, Issue 2, 2000, Pages 123-127

  Mazarati, Andrey M ^a,b,e   Baldwin, Roger A ^a   Sofia, R Duane ^d   Wasterain, Claude G ^a,b,c  

^a VA Gtr Los Angeles Hlthcare System   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Wallace Laboratories   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anticonvulsant; Felbamate; Seizures; Self sustaining status epilepticus

Indexed keywords

DIAZEPAM; FELBAMATE; PHENYTOIN;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033969184     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb00130.x     Document Type: Article

References (20)

1. DeLorenzo RJ, Pellock JM, Towne A, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol 1995;12:316-25.
2. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996;46:1029-35.
3. Mazarati AM, Wasterlain CG, Sankar R, Shin D. Self-sustaining status epilepticus after brief electrical stimulation of the perforant path. Brain Res 1998;801:251-3.
4. Mazarati AM, Baldwin RA, Sankar R, Wasterlain CG. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res 1998; 814:179-85.
5. Mazarati AM, Wasterlain CG. NMDA receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett 1999;265:187-90.
6. 3H]glycine binding in rat brain and sections of human postmortem brain. J Pharmacol Exp Ther 1998;286:991-9.
7. 3H]DCKA-labeled strychnine-insensitive glycine receptors in human postmortem brain. Exp Neurol 1994;129:244-50.
8. McCabe RT, Wasterlain CG, Kucharczyk N, Sofia RD, Vogel JR. Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther 1993;264:1248-52.
9. Leppik IE, Dreifuss FE, Pledger GW. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991;41: 1785-9.
10. Wasterlain CG, Adams LM, Hattori H, Schwartz PH. Felbamate reduces hypoxic-ischemic brain damage in vivo. Eur J Pharmacol 1992;212:275-8.
11. Wasterlain CG, Adams LM, Schwartz PH, Hattori H, Sofia RD, Wichmann JK. Posthypoxic treatment with felbamate is neuroprotective in a rat model of hynoxia-ischemia. Neurology 1993;43: 2303-10.
12. Wasterlain CG, Adams LM, Wichmann JK, Sofia RD. Felbamate protects CA1 neurons from apoptosis in a gerbil model of global ischemia. Stroke 1996;27:1236-40.
13. Sankar R, Shin DH, Wasterlain CG. Serum neurom-specific enoase is a marker for neuronal damage following status epilepticus in the rat. Epilepsy Res 1997;28:129-36.
14. Paxinos G, Watson C. The rat brain in stereotaxic coordinates.2nd ed. San Diego: Academic Press, 1986.
15. Sofia RD, Gordon R, Gels M, Diamantis W. Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat. Res Commun Chem Pathol Pharmacol 1993;73:1-3.
16. Theodore WH, Reeves P, Porter RJ, Nice FJ, Derinsky O, Bromfield E, Balish M. Long-term followup of felbamate therapy in patients with complex partial seizures. Epilepsia 1990;31:619.
17. Wagner ML, Leppik IE, Graves NM, Remme RP, Campbell JI. Felbamate serum concentrations: effect of valproate, carbamazepine, phenytoin and phenobarbital. Epilepsia 1990;31:642.
18. Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 1986;27:27-34.
19. Pennel PB, Ogaily MS, MacDonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995;45:456-60.
20. Wallace Laboratories, data on file.